DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

New look. Same commitment. Decision Resources Group becomes Clarivate. Read more here

    Pancreatic Cancer Epidemiological Forecast

    DRG Epidemiology’s global epidemiology forecast for pancreatic cancer offers 10 year (20 years in the G7) epidemiological forecasts for 45 countries, covering 90% of the world’s population for all of the following pancreatic cancer patient populations:

    • Diagnosed incident cases
    • Diagnosed incident cases by stage at diagnosis and resection status
    • Adjuvant and 1st – line metastatic (and 2nd – line in the G7) drug-treatable population
    • Diagnosed prevalent cases of pancreatic cancer

    In addition, estimates of the drug-treated prevalent population are also available for United States, France, Germany, Italy, Spain, United Kingdom and Japan.

    DRG Epidemiology’s estimates are presented in DRG’s Insights Platform, allowing the user to easily navigate between world regions and patient populations, as well as download the data in Excel formatted files.

    All of our epidemiological forecasts are accompanied by a transparent description of our forecast methods and data sources, the details of our systematic review underlying each forecast and associated summary evidence tables, and access to the authoring epidemiologist. All epidemiological forecasts may be supplemented with custom deliverables, such as:

    • Chart reviews using DRG’s in-house real world datasets or physician survey data
    • More detailed patient flow models or additional subpopulations or metrics
    • Coverage of countries or extended forecast periods beyond those available